Case Reports
Vol. 71 No. 2 (2019)
https://doi.org/10.4081/reumatismo.2019.1115
Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 31 December 2017
Published: 9 July 2019
Published: 9 July 2019
1629
Views
1045
Downloads
Anti-tumor necrosis factor drugs are used routinely according to treatment guidelines for several chronic rheumatologic problems. However, a rare and usually unpredictable adverse drug reaction namely peripheral nervous system demyelination is being increasingly recognized. Biosimilars are gaining momentum especially in countries like India. Hence, we report a case of Guillain-Barré syndrome secondary to an etanercept biosimilar, probably the first case reported so far.
Downloads
Download data is not yet available.
How to Cite
1.
Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case. Reumatismo [Internet]. 2019 Jul. 9 [cited 2026 Aug. 30];71(2):99-102. Available from: https://www.reumatismo.org/reuma/article/view/1115
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
